FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334193406> ?p ?o ?g. }

• W2334193406 endingPage "727" @default.
• W2334193406 startingPage "716" @default.
• W2334193406 abstract "Glioblastoma is a disease characterized by rapid invasive tumour growth. Studies on the proapoptotic CD95/CD95L signalling pathway recently suggested a significant contribution of CD95 signalling towards the high degree of motility in glioma cells. Apogenix has developed APG101, a clinical phase II compound designed to bind and neutralize CD95L, and thus to interfere with CD95/CD95L-based signalling. APG101 has shown clinical efficacy in a controlled randomized phase II trial in patients with recurrent glioma. Because APG101 is not cytotoxic to tumour cells in vitro, we postulated that the anti-invasive function of APG101 is the main mechanism of action for this compound. Using three-dimensional spheroid invasion assays in vitro and in murine brain tissue cultures, we found that knockdown of endogenous CD95L reduced the invasive phenotype in our two glioblastoma model cell lines U87-MG and U251-MG. Invasion was restored in CD95L knockdown cells upon the addition of soluble recombinant CD95L and this effect was inhibited by APG101. We conclude that CD95L from autocrine and paracrine sources contributes towards the invasive phenotype of glioblastoma cells and that APG101 acts as a suppressor of proinvasive signalling by the CD95/CD95L pathway in glioblastoma." @default.
• W2334193406 created "2016-06-24" @default.
• W2334193406 creator A5011184461 @default.
• W2334193406 creator A5013217770 @default.
• W2334193406 creator A5015350812 @default.
• W2334193406 creator A5019911093 @default.
• W2334193406 creator A5024872255 @default.
• W2334193406 creator A5028313527 @default.
• W2334193406 creator A5037806609 @default.
• W2334193406 creator A5053232413 @default.
• W2334193406 date "2015-08-01" @default.
• W2334193406 modified "2023-10-01" @default.
• W2334193406 title "Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro" @default.
• W2334193406 cites W1642763135 @default.
• W2334193406 cites W1983517349 @default.
• W2334193406 cites W1992737970 @default.
• W2334193406 cites W2032560191 @default.
• W2334193406 cites W2039856166 @default.
• W2334193406 cites W2042258261 @default.
• W2334193406 cites W2073338516 @default.
• W2334193406 cites W2078677652 @default.
• W2334193406 cites W2088308416 @default.
• W2334193406 cites W2088411078 @default.
• W2334193406 cites W2104329553 @default.
• W2334193406 cites W2104790339 @default.
• W2334193406 cites W2110039252 @default.
• W2334193406 cites W2117692326 @default.
• W2334193406 cites W2119928565 @default.
• W2334193406 cites W2132635116 @default.
• W2334193406 cites W2132954482 @default.
• W2334193406 cites W2145611701 @default.
• W2334193406 doi "https://doi.org/10.1097/cad.0000000000000237" @default.
• W2334193406 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4484665" @default.
• W2334193406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25850884" @default.
• W2334193406 hasPublicationYear "2015" @default.
• W2334193406 type Work @default.
• W2334193406 sameAs 2334193406 @default.
• W2334193406 citedByCount "24" @default.
• W2334193406 countsByYear W23341934062016 @default.
• W2334193406 countsByYear W23341934062017 @default.
• W2334193406 countsByYear W23341934062018 @default.
• W2334193406 countsByYear W23341934062019 @default.
• W2334193406 countsByYear W23341934062020 @default.
• W2334193406 countsByYear W23341934062021 @default.
• W2334193406 countsByYear W23341934062022 @default.
• W2334193406 countsByYear W23341934062023 @default.
• W2334193406 crossrefType "journal-article" @default.
• W2334193406 hasAuthorship W2334193406A5011184461 @default.
• W2334193406 hasAuthorship W2334193406A5013217770 @default.
• W2334193406 hasAuthorship W2334193406A5015350812 @default.
• W2334193406 hasAuthorship W2334193406A5019911093 @default.
• W2334193406 hasAuthorship W2334193406A5024872255 @default.
• W2334193406 hasAuthorship W2334193406A5028313527 @default.
• W2334193406 hasAuthorship W2334193406A5037806609 @default.
• W2334193406 hasAuthorship W2334193406A5053232413 @default.
• W2334193406 hasBestOaLocation W23341934061 @default.
• W2334193406 hasConcept C128240485 @default.
• W2334193406 hasConcept C154317977 @default.
• W2334193406 hasConcept C170493617 @default.
• W2334193406 hasConcept C173396325 @default.
• W2334193406 hasConcept C185592680 @default.
• W2334193406 hasConcept C190283241 @default.
• W2334193406 hasConcept C202751555 @default.
• W2334193406 hasConcept C2778227246 @default.
• W2334193406 hasConcept C3031857 @default.
• W2334193406 hasConcept C31573885 @default.
• W2334193406 hasConcept C502942594 @default.
• W2334193406 hasConcept C54355233 @default.
• W2334193406 hasConcept C55493867 @default.
• W2334193406 hasConcept C7876069 @default.
• W2334193406 hasConcept C81885089 @default.
• W2334193406 hasConcept C86803240 @default.
• W2334193406 hasConcept C95444343 @default.
• W2334193406 hasConceptScore W2334193406C128240485 @default.
• W2334193406 hasConceptScore W2334193406C154317977 @default.
• W2334193406 hasConceptScore W2334193406C170493617 @default.
• W2334193406 hasConceptScore W2334193406C173396325 @default.
• W2334193406 hasConceptScore W2334193406C185592680 @default.
• W2334193406 hasConceptScore W2334193406C190283241 @default.
• W2334193406 hasConceptScore W2334193406C202751555 @default.
• W2334193406 hasConceptScore W2334193406C2778227246 @default.
• W2334193406 hasConceptScore W2334193406C3031857 @default.
• W2334193406 hasConceptScore W2334193406C31573885 @default.
• W2334193406 hasConceptScore W2334193406C502942594 @default.
• W2334193406 hasConceptScore W2334193406C54355233 @default.
• W2334193406 hasConceptScore W2334193406C55493867 @default.
• W2334193406 hasConceptScore W2334193406C7876069 @default.
• W2334193406 hasConceptScore W2334193406C81885089 @default.
• W2334193406 hasConceptScore W2334193406C86803240 @default.
• W2334193406 hasConceptScore W2334193406C95444343 @default.
• W2334193406 hasIssue "7" @default.
• W2334193406 hasLocation W23341934061 @default.
• W2334193406 hasLocation W23341934062 @default.
• W2334193406 hasLocation W23341934063 @default.
• W2334193406 hasLocation W23341934064 @default.
• W2334193406 hasLocation W23341934065 @default.
• W2334193406 hasOpenAccess W2334193406 @default.
• W2334193406 hasPrimaryLocation W23341934061 @default.

• next